Page last updated: 2024-09-05

sorafenib and Hematologic Neoplasms

sorafenib has been researched along with Hematologic Neoplasms in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	5 (83.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cheng, SB; Huang, CC; Jan, YG; Lin, HC; Lin, YL; P'eng, FK; Shen, CH; Teng, CJ; Wu, CC; Yang, YS	1
Adamia, S; Buhrlage, SJ; Case, AE; Dubreuil, P; Gokhale, PC; Gray, N; Griffin, JD; Letard, S; Liu, X; Meng, C; Sattler, M; Stone, RM; Tiv, HL; Wang, J; Weisberg, E; Yang, J	1
Bloor, A; Cross, NC; Erben, P; Gesk, S; Haferlach, C; Haferlach, T; Hochhaus, A; Hofmann, WK; Metzgeroth, G; Reiter, A; Ritter, M; Score, J; Telford, N; Walz, C	1
Anderson, KC; Podar, K	1
Secchiero, P; Tisato, V; Voltan, R; Zauli, G	1
Clemetson, KJ	1

Reviews

2 review(s) available for sorafenib and Hematologic Neoplasms

Article	Year
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies. Current cancer drug targets, 2011, Volume: 11, Issue:9 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway	2011
State of the art of the therapeutic perspective of sorafenib against hematological malignancies. Current medicinal chemistry, 2012, Volume: 19, Issue:28 Topics: Apoptosis; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Receptors, Vascular Endothelial Growth Factor; Sorafenib; TNF-Related Apoptosis-Inducing Ligand	2012

Article

Year

Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.

Current cancer drug targets, 2011, Volume: 11, Issue:9

Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway

2011

State of the art of the therapeutic perspective of sorafenib against hematological malignancies.

Current medicinal chemistry, 2012, Volume: 19, Issue:28

Topics: Apoptosis; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Receptors, Vascular Endothelial Growth Factor; Sorafenib; TNF-Related Apoptosis-Inducing Ligand

2012

Other Studies

4 other study(ies) available for sorafenib and Hematologic Neoplasms

Article	Year
Liver resection for hepatocellular carcinoma in patients with hematological malignancies. World journal of surgical oncology, 2017, Nov-02, Volume: 15, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Hematologic Neoplasms; Hepacivirus; Hepatectomy; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Niacinamide; Patient Selection; Phenylurea Compounds; Postoperative Complications; Prognosis; Retrospective Studies; Serologic Tests; Sorafenib; Survival Rate; Young Adult	2017
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. British journal of haematology, 2019, Volume: 187, Issue:4 Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Mutant Proteins; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Proto-Oncogene Proteins c-kit; Pyrazines; Pyrazoles; Pyrroles; Sorafenib; Staurosporine; Triazines	2019
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. Blood, 2011, Aug-25, Volume: 118, Issue:8 Topics: Adult; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Benzenesulfonates; DNA, Neoplasm; Drug Resistance, Neoplasm; Eosinophilia; ETS Translocation Variant 6 Protein; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Indoles; Male; Middle Aged; Molecular Sequence Data; Niacinamide; Oncogene Fusion; Oncogene Proteins, Fusion; Phenylurea Compounds; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ets; Pyridines; Pyrroles; Repressor Proteins; Sorafenib; Sunitinib	2011
American Society of Hematology--48th Annual Meeting and Exposition. Updates on therapies. 9-12 December 2006 Orlando, FL, USA. IDrugs : the investigational drugs journal, 2007, Volume: 10, Issue:2 Topics: Anemia, Sickle Cell; Antibiotics, Antineoplastic; Antigens, CD20; Benzamides; Benzenesulfonates; CD40 Antigens; Diphenylamine; Hematologic Neoplasms; Hematology; Humans; Ki-1 Antigen; Leukemia, Myeloid; Lymphoma; MAP Kinase Kinase Kinases; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib	2007